• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Vericel Corporation

    2/12/25 4:08:24 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VCEL alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001214938
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Vericel Corp
    SEC File Number
    001-35280
    Address of Issuer
    64 SIDNEY ST.
    CAMBRIDGE
    MASSACHUSETTS
    02139
    Phone
    7349305555
    Name of Person for Whose Account the Securities are To Be Sold
    MCLAUGHLIN KEVIN F
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    7000388236.164935840802/12/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common02/12/2025Option Granted 03/20/2015IssuerCheckbox not checked600002/12/2025Cash
    Common02/12/2025Option Granted 05/04/2016IssuerCheckbox not checked100002/12/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Kevin Mclaughlin
    64 Sidney Street
    Cambridge � MA � 02139
    Common11/13/20247000388802.40

    144: Remarks and Signature

    Remarks
    Date of Notice
    02/12/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    03/11/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jackson Harris, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Kevin F Mclaughlin

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $VCEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VCEL

    DatePrice TargetRatingAnalyst
    9/17/2025Buy → Neutral
    BTIG Research
    8/9/2024$57.00Buy
    Canaccord Genuity
    6/20/2024$55.00Buy
    TD Cowen
    1/25/2024$39.00 → $51.00Hold → Buy
    Truist
    8/8/2023$39.00Neutral → Buy
    BTIG Research
    11/10/2022Buy → Neutral
    BTIG Research
    11/9/2022Buy → Hold
    Truist
    10/14/2022$40.00Overweight
    Stephens
    More analyst ratings

    $VCEL
    SEC Filings

    View All

    Vericel Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vericel Corp (0000887359) (Filer)

    1/13/26 9:11:04 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Vericel Corporation

    SCHEDULE 13G/A - Vericel Corp (0000887359) (Subject)

    11/12/25 4:43:04 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Vericel Corporation

    SCHEDULE 13G - Vericel Corp (0000887359) (Subject)

    11/10/25 9:05:27 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026

    CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the web

    2/12/26 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel Announces Preliminary 2025 Financial Results and Business Updates

    Total Revenue Expected to be $276 Million  MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary, unaudited financial results and other business updates for the fourth quarter and year ended December 31, 2025. Preliminary, Unaudited Full-Year 2025 Financial Results Total net revenue expected to be approximately $276 million, with MACI® net revenue of $239.5 million and Burn Care net revenue of $36.5 millionGross margin expected to be 74% an

    1/13/26 9:00:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026

    CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference at 2:15 p.m. ET (11:15 a.m. PT) on Wednesday, January 14, 2026. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting

    1/6/26 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $VCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chief Operating Officer Halpin Michael exercised 10,000 shares at a strike of $16.66 and sold $404,800 worth of shares (10,000 units at $40.48) (SEC Form 4)

    4 - Vericel Corp (0000887359) (Issuer)

    1/9/26 4:05:33 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Human Resources Officer Mahoney Karen converted options into 2,625 shares and covered exercise/tax liability with 771 shares (SEC Form 4)

    4 - Vericel Corp (0000887359) (Issuer)

    12/12/25 4:05:17 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Wotton Paul K sold $189,500 worth of shares (5,000 units at $37.90), decreasing direct ownership by 16% to 25,602 units (SEC Form 4)

    4 - Vericel Corp (0000887359) (Issuer)

    12/4/25 4:05:27 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel downgraded by BTIG Research

    BTIG Research downgraded Vericel from Buy to Neutral

    9/17/25 7:57:35 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Canaccord Genuity initiated coverage on Vericel with a new price target

    Canaccord Genuity initiated coverage of Vericel with a rating of Buy and set a new price target of $57.00

    8/9/24 8:07:19 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on Vericel with a new price target

    TD Cowen initiated coverage of Vericel with a rating of Buy and set a new price target of $55.00

    6/20/24 7:39:49 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Financials

    Live finance-specific insights

    View All

    Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026

    CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the web

    2/12/26 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel Reports Third Quarter 2025 Financial Results

    Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow of $22.1 Million More than 800 MACI Arthro Surgeons Trained to Date Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Total net revenue of $67.5 millionMACI® net revenue growth o

    11/6/25 7:55:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025

    CAMBRIDGE, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its third-quarter 2025 financial results on Thursday, November 6, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be ava

    10/23/25 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vericel Corporation

    SC 13G/A - Vericel Corp (0000887359) (Subject)

    11/14/24 1:46:57 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vericel Corporation

    SC 13G/A - Vericel Corp (0000887359) (Subject)

    11/14/24 6:19:59 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vericel Corporation

    SC 13G/A - Vericel Corp (0000887359) (Subject)

    10/18/24 12:21:30 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Leadership Updates

    Live Leadership Updates

    View All

    Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer

    CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel's Head of Human Resources since September 2010. Ms. Mahoney joins Vericel with more than 20 years of experience across the life sciences and medical device sectors, most recently serving as Chief Human Resources Officer at Abiomed, a global medical device company that was acquired by Johnson & Johnson in December 2022. At Abiomed, Ms. Mahoney led all aspects of HR strategy and

    7/22/24 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    A-Alpha Bio Welcomes Heidi Hagen to Its Board of Directors

    Hagen, Former Chief Technical Officer of Sonoma Biotherapeutics, Joins as A-Alpha's First Independent Board Member SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors. Hagen will be A-Alpha Bio's first independent board member. Hagen has been a leader in the Biotechnology industry for 30 years. Over the course of her career, she has built an extensive track record in leading strategy and operations to progress innovative technologies from ideation to commercialization. Having been a core member of pharma companie

    6/27/23 9:00:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors

    New Independent Board Chair, Dr. Paul K. Wotton, brings 35 years of experience building private and public biopharmaceutical companies with significant business development expertise. Kytopen, an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to Chair the Kytopen Board of Directors. Following the appointment of Dr. Wotton, the Board will comprise of five directors including Ann DeWitt, Adam Wieschhaus, Cullen Buie, and Paulo Garcia. Dr. Paul Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham and is an experienced CEO,

    1/5/23 9:00:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care